Cagrilintide – 10mg (10-Vial Research Kit)
CJC-1295 & Ipamorelin is a dual-pathway research peptide blend combining a growth hormone–releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R) agonist. This formulation is widely studied for its potential synergistic influence on growth hormone (GH) secretion in controlled laboratory environments.
CJC-1295 is a modified GHRH analogue designed to stimulate endogenous GH release via the GHRH receptor pathway, while Ipamorelin selectively activates ghrelin receptors, offering targeted GH modulation with minimal off-target endocrine activity in research models.
When combined, these peptides provide a complementary mechanism of action that allows researchers to explore pulsatile GH release through multiple signaling pathways.
Research Applications
This peptide blend is commonly studied to:
Investigate simultaneous activation of GHRH and ghrelin receptor pathways
Explore growth hormone signaling and endocrine regulation
Support research into cellular repair, recovery, and regeneration
Assess metabolic responses associated with GH modulation
Examine GH release patterns without significant elevation of cortisol or prolactin, as observed in research models
Reconstitution Instructions
Reconstitute with Bacteriostatic (BAC) water before use.
Refrigerate after reconstitution and handle under sterile laboratory conditions.
Use our Peptide Calculator for accurate preparation.
For laboratory research use only. Not for human consumption.
){kind=link}